Invega Hafyera (Paliperidone Palmitate) Patent Expiration, LOE Window & CMS Spending

Invega Hafyera (Paliperidone Palmitate) by Johnson & Johnson: FDA Orange Book LOE 2041-11-24, 11 AB generics, $202.4M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN207946 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-11-24
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$202.4M
2024 Medicare Part D Spend$109.4M
2024 Medicaid Spend$93.0M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 18.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.